CD8A and esophageal squamous cell carcinoma: The PD−1/PDL-1 pathway can prevent effective antitumor immunity by downregulating the function of CD8+ T lymphocytes, so ESCC patients who are PDL-1−positive have a poorer prognosis than negative patients (30).